OO095 - PLASMA NEUROFILAMENT LIGHT AS A MARKER OF PSYCHOSIS IN PARKINSON'S DISEASE (ID 426)
Abstract
Aims
Neuropsychiatric symptoms (NPS) are common to Parkinson’s disease (PD) but their aetiology is poorly understood. Plasma neurofilament light (NfL) is a biomarker of neuroaxonal degeneration which has yet to be explored in association with the NPS in PD. We aimed to investigate the longitudinal relationship between NfL and psychotic and affective symptoms in PD.
Methods
We evaluated the association of NPS with NfL in a cohort (n = 144; PD = 106, healthy controls (HC) = 38). Plasma NfL was measured at baseline and NPS were measured with Non-Motor Symptom Scale (NMSS) for psychotic symptoms and Hospital Anxiety and Depression Scale (HADS) for affective symptoms. A subset of patients (n=61) were assessed annually for NPS. NPS were quantified dichotomously on a cumulative basis as they were developed during the study.
Results
73 (86%) PD patients developed NPS at some time point in the study; 37 with psychotic symptoms and 70 with affective symptoms. Plasma NfL was elevated in patients who developed psychotic symptoms in age-adjusted logistic regression (OR 3.81 [1.06-13.7], p=0.04). There was no association between NfL concentration and affective symptoms.
Conclusions
These findings suggest cumulative psychotic symptoms are associated with greater neurodegeneration in PD. It suggests differing neurobiological aetiologies underpinning the psychotic and affective symptoms seen in PD. Further studies are needed to explore NfL as a potential prognostic biomarker for psychotic symptoms in PD.
Audio MP3
HidePrevious ePoster
Next ePosters
